Cerevance
Cambridge
United Kingdom
About Cerevance
Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology.64 articles with Cerevance
-
Cerevance to Participate in Chief Medical Officer Summit 360˚
3/27/2023
Cerevance today announced that Ottavio V. Vitolo, M.D., chief medical officer of Cerevance, will participate in a roundtable discussion at the upcoming Chief Medical Officer Summit 360.
-
Cerevance Announces Presentations at Two Medicinal Chemistry Conferences
3/21/2023
Cerevance today announced plans to present at two upcoming medicinal chemistry conferences.
-
Cerevance Announces Presentations at AD/PD™ 2023 International Conference
3/20/2023
Cerevance today announced plans to present two symposium oral presentations and a poster presentation at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Gothenburg, Sweden, March 28 – April 1, 2023.
-
Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023
3/7/2023
Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
-
Cerevance Expands Series B Financing with Additional $51 Million
2/13/2023
Cerevance, a private announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million.
-
Cerevance to Participate at the SVB Global Biopharma Conference
1/24/2023
Cerevance announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.
-
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
1/9/2023
Cerevance today announced positive results from its Phase 1 study of CVN766 in healthy subjects.
-
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
12/7/2022
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.
-
Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology
11/30/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the presentation of preclinical data supporting the use of the company’s Nuclear Enriched Sort sequencing (NETSseq) technology platform to identify novel, druggable targets involved in the regulation of neuroinflammation in Alzheimer’s disease (AD).
-
Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference
11/15/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced the presentation of preclinical study results during the poster session held November 14th at the Society for Neuroscience (SFN) 2022 conference in San Diego, California.
-
Cerevance to Present at the Society for Neuroscience (SFN) 2022
11/7/2022
Cerevance today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
Cerevance Appoints Ottavio V. Vitolo, M.D., as Chief Medical Officer
10/3/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced the appointment of Ottavio V. Vitolo, M.D. as chief medical officer.
-
Using Cerevance’s proprietary NNETSseq technology platform, Merck and Cerevance have partnered to identify new targets for the treatment of Alzheimer’s disease.
-
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
8/9/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
-
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
6/8/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced that Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
4/19/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson to chief executive officer.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.